Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.300 Biomarker group CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0027765
Disease: nervous system disorder
nervous system disorder 		0.300 Biomarker group CTD_human A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles. 23203475 2013
CUI: C0153633
Disease: Malignant neoplasm of brain
Malignant neoplasm of brain 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0496899
Disease: Benign neoplasm of brain, unspecified
Benign neoplasm of brain, unspecified 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750974
Disease: Brain Tumor, Primary
Brain Tumor, Primary 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750977
Disease: Recurrent Brain Neoplasm
Recurrent Brain Neoplasm 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0750979
Disease: Primary malignant neoplasm of brain
Primary malignant neoplasm of brain 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C1527390
Disease: Neoplasms, Intracranial
Neoplasms, Intracranial 		0.300 Biomarker group CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
CUI: C0206694
Disease: Mucoepidermoid Carcinoma
Mucoepidermoid Carcinoma 		0.020 Biomarker disease BEFREE Analyses of potential downstream targets of the fusion revealed differential expression of the cAMP/CREB (FLT1 and NR4A2) and Notch (HES1 and HES5) target genes in fusion-positive and fusion-negative MECs. 16444749 2006
CUI: C0206694
Disease: Mucoepidermoid Carcinoma
Mucoepidermoid Carcinoma 		0.020 Biomarker disease BEFREE Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion. 14720503 2004
CUI: C0598608
Disease: Hyperhomocysteinemia
Hyperhomocysteinemia 		0.020 Biomarker disease BEFREE These results suggest that HHcy-enhanced brain damage is associated with increased autophagy and neuronal apoptosis in Apo E<sup>-/-</sup> mice, in which downregulation of hes1 and hes5 is involved. 29171783 2017
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.010 Biomarker disease BEFREE Taken together, out data have delineated that HES5 might contribute to the proliferation of NSCLC by STAT3 signaling. 27878283 2017
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy 		0.010 Biomarker disease BEFREE Main conclusions allow certifying that crucial pathways related to Wnt-MAPK signaling pathways or neuroinflammation are epigenetically controlled in the fibrotic disorders involved in retinal detachment, but results also reinforced the contribution of neurovascularization (ETS1, HES5, PRDM16) in diabetic retinopathy. 28924151 2017
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.010 Biomarker disease BEFREE Notch signaling receptors NOTCH1 and NOTCH4, ligands JAGGED2 and DLL4, as well as direct target genes HES5 and HEY1 were decreased in the eutopic endometrium of women and baboons with endometriosis. 25546156 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.010 Biomarker disease BEFREE Multiple myeloma cell growth relies on intrinsic aggressiveness, due to a high karyotypic instability, or on the support from bone marrow (BM) niche.We and other groups have provided evidences that Notch signaling is related to tumor cell growth, pharmacological resistance, localization/recirculation in the BM and bone disease.This study indicates that high gene expression levels of Notch signaling members (JAG1, NOTCH2, HES5 and HES6) correlate with malignant progression or high-risk disease, and Notch signaling may participate in myeloma progression by increasing the BM levels of interleukin-6 (IL-6), a major player in myeloma cell growth and survival. 27463014 2016
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 Biomarker phenotype BEFREE Either Hes1 or Hes5 overactivation is likely to affect cell differentiation, thereby resulting in carcinogenesis. 21495212 2010
CUI: C0852949
Disease: Arteriopathic disease
Arteriopathic disease 		0.010 Biomarker group BEFREE Treatment with GTPs upregulated the levels of Jagged1, Notch1, Hes5, p-STAT3, and MnSOD2, and downregulated xanthine oxidase (XO) expression in rats with preglomerular arteriopathy. 30416668 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 Biomarker phenotype BEFREE HES5 promotes cell proliferation and invasion through activation of STAT3 and predicts poor survival in hepatocellular carcinoma. 26342546 2015
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis 		0.010 Biomarker disease BEFREE Therefore, we have characterized HES5 and investigated its role during hepatocarcinogenesis. 26342546 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 PosttranslationalModification disease BEFREE The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine. 21744479 2012
CUI: C1292769
Disease: Precursor B-cell lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia 		0.010 PosttranslationalModification disease BEFREE 5-aza-2'-deoxycytidine treatment restored Hes5 expression and decreased promoter hypermethylation in most leukemia cell lines and primary B-ALL samples. 23637910 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 AlteredExpression group BEFREE Multiple myeloma cell growth relies on intrinsic aggressiveness, due to a high karyotypic instability, or on the support from bone marrow (BM) niche.We and other groups have provided evidences that Notch signaling is related to tumor cell growth, pharmacological resistance, localization/recirculation in the BM and bone disease.This study indicates that high gene expression levels of Notch signaling members (JAG1, NOTCH2, HES5 and HES6) correlate with malignant progression or high-risk disease, and Notch signaling may participate in myeloma progression by increasing the BM levels of interleukin-6 (IL-6), a major player in myeloma cell growth and survival. 27463014 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 AlteredExpression group BEFREE Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion. 14720503 2004